These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29293242)

  • 1. Drug pricing should depend on shared values.
    Ramsey S
    Nature; 2017 Dec; 552(7685):S78. PubMed ID: 29293242
    [No Abstract]   [Full Text] [Related]  

  • 2. Kymriah: A Sign of More Difficult Decisions To Come.
    Silverman E
    Manag Care; 2018 May; 27(5):17. PubMed ID: 29763402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 4. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
    Brower V
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.
    Nam J; Milenkovski R; Yunger S; Geirnaert M; Paulson K; Seftel M
    J Med Econ; 2018 Jan; 21(1):47-59. PubMed ID: 28837377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising gene therapies pose million-dollar conundrum.
    Check Hayden E
    Nature; 2016 Jun; 534(7607):305-6. PubMed ID: 27306167
    [No Abstract]   [Full Text] [Related]  

  • 8. Amgen swallows Micromet to BiTE into ALL market.
    Sheridan C
    Nat Biotechnol; 2012 Apr; 30(4):300-1. PubMed ID: 22491268
    [No Abstract]   [Full Text] [Related]  

  • 9. Developers seek to finetune toxicity of T-cell therapies.
    Morrison C
    Nat Biotechnol; 2014 Dec; 32(12):1171-2. PubMed ID: 25489817
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic evaluation of treatment for acute lymphoblastic leukaemia in childhood.
    Rae C; Furlong W; Jankovic M; Moghrabi A; Naqvi A; Sala A; Samson Y; DePauw S; Feeny D; Barr R
    Eur J Cancer Care (Engl); 2014 Nov; 23(6):779-85. PubMed ID: 24393150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attack of the killer clones.
    Scudellari M
    Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
    [No Abstract]   [Full Text] [Related]  

  • 12. The scandal of generic drug pricing: drug regulation policies need review.
    Meeran K; Choudhury SM; Wass J
    BMJ; 2017 Feb; 356():j947. PubMed ID: 28232321
    [No Abstract]   [Full Text] [Related]  

  • 13. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.
    Dranitsaris G; Truter I; Lubbe MS; Cottrell W; Spirovski B; Edwards J
    J Eval Clin Pract; 2012 Apr; 18(2):343-51. PubMed ID: 21087368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's in a perspective?
    Glick HA
    Value Health; 2010; 13(1):2. PubMed ID: 19912594
    [No Abstract]   [Full Text] [Related]  

  • 15. Product listing agreements (PLAs): a new tool for reaching Quebec's pharmaceutical policy objectives?
    Bourassa Forcier M; Noël F
    Healthc Policy; 2013 Aug; 9(1):65-75. PubMed ID: 23968675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Not cost-effective at zero price: valuing and paying for combination therapies in cancer.
    Latimer NR; Towse A; Henshall C
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):331-333. PubMed ID: 33472440
    [No Abstract]   [Full Text] [Related]  

  • 17. Collaborating to conquer cancer: lessons from our children.
    Link MP
    J Clin Oncol; 2013 Mar; 31(7):825-32. PubMed ID: 23341511
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy: CAR-modified T cells targeting CD19-curing the incurable.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25348787
    [No Abstract]   [Full Text] [Related]  

  • 19. Choosing chemotherapy for lung cancer based on cost: not yet.
    Roberts TG; Lynch TJ; Chabner BA
    Oncologist; 2002; 7(3):177-8. PubMed ID: 12065787
    [No Abstract]   [Full Text] [Related]  

  • 20. Ethical and value issues in insurance coverage for cancer treatment.
    Brock DW
    Oncologist; 2010; 15 Suppl 1():36-42. PubMed ID: 20237216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.